Sage Therapeutics, Inc. (NasdaqGM:SAGE) has an ERP5 rank of 17330. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The lower the ERP5 rank, the more undervalued a company is thought to be.

It can be very difficult to keep emotions on the sidelines when making important investing decisions. Even if all the number crunching is done unemotionally, there may be a tendency for those feelings of excitement or dread to creep in. Once the trade is made, it can be super difficult to make sane decisions when markets go haywire. Investors may have made some trades that didn’t pan out as planned, and they may have the itch to sell quickly in order to stop further losses. Selling a stock just because it is going down or buying a stock just because it is going up, might lead to portfolio struggles in the future. Obtaining a grasp on the bigger picture may help investors see through the cloudiness and make clearer decisions when the time comes.

The Q.i. Value of Sage Therapeutics, Inc. (NasdaqGM:SAGE) is 64.00000. The Q.i. Value is another helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

**Technicals**

The EBITDA Yield is a great way to determine a company’s profitability. This number is calculated by dividing a company’s earnings before interest, taxes, depreciation and amortization by the company’s enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The EBITDA Yield for Sage Therapeutics, Inc. (NasdaqGM:SAGE) is -0.072616.

The Earnings to Price yield of Sage Therapeutics, Inc. (NasdaqGM:SAGE) is -0.056302. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance. Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Sage Therapeutics, Inc. (NasdaqGM:SAGE) is -0.072828. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for Sage Therapeutics, Inc. is -0.028213.

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of Sage Therapeutics, Inc. (NasdaqGM:SAGE) is -0.022194.

**Ratios**

The Current Ratio of Sage Therapeutics, Inc. (NasdaqGM:SAGE) is 19.07. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company might have trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.

The Leverage Ratio of Sage Therapeutics, Inc. (NasdaqGM:SAGE) is 0.000000. Leverage ratio is the total debt of a company divided by total assets of the current and past year divided by two. Companies take on debt to finance their day to day operations. The leverage ratio can measure how much of a company’s capital comes from debt. With this ratio, investors can better estimate how well a company will be able to pay their long and short term financial obligations.

The price to book ratio or market to book ratio for Sage Therapeutics, Inc. (NasdaqGM:SAGE) currently stands at 5.101355. The ratio is calculated by dividing the stock price per share by the book value per share. This ratio is used to determine how the market values the equity. A ratio of under 1 typically indicates that the shares are undervalued. A ratio over 1 indicates that the market is willing to pay more for the shares. There are often many underlying factors that come into play with the Price to Book ratio so all additional metrics should be considered as well.

Stock market investing can sometimes be a wild ride. High volatility stocks may seem to constantly going haywire. Finding a comfortable balance between stomach turning stocks and low volatility stable stocks may be the way to go. Building confidence in the stock portfolio may come with some trial and error for the individual investor. Many people will rely on others to actively manage their money, but there are always those who prefer to have a hand in every aspect of their hard earned cash. Staying on top of the markets may seem impossible sometimes. There is always something happening, and keeping the pulse on market movements may be quite a struggle. Applying the proper amount of time to dedicate for stock research might just be the difference between buying that next big winner or getting stuck with a big loser.

**Adding it All Up**

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of Sage Therapeutics, Inc. (NasdaqGM:SAGE) is 4. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Sage Therapeutics, Inc. (NasdaqGM:SAGE) is 50.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

Investors may be watching the ebb and flow of the current market environment and be wondering what the next few months have in store. They may be deciding whether now is a good time to sell off some first half winners or hold on for further gains. This can be one of the toughest decisions that an investor has to make. Just because a stock has been steadily heading higher for an extended period of time doesn’t necessarily mean that it will continue to do so. Building the confidence to make the tough portfolio decisions may take some time and a few good trades under the belt. New investors may be prone to get discouraged after a few sour trades in a row. Anyone who wants to succeed in the stock market knows that there is no substitute for research and hard work. Being able to bounce back and learn from mistakes may help the investor stay in the game and get back on the road to healthy profits.

**Receive News & Ratings Via Email** - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.